Jiangsu Hengrui Medicine in-licensed greater China rights to a treatment for chronic yeast infections from Mycovia Pharma of Durham, North Carolina. Mycovia is currently conducting a Phase III trial of VT-1161 (otesaconazole) in women with recurrent vulvovaginal candidiasis (RVVC) in the US, the EU and Japan. A novel oral therapy, VT-1161 is designed to have greater selectivity, fewer side effects and improved potency than current treatments. Mycovia believes it may also be effective for other systemic fungal infections.
Source: China Biotoday
